Charles River(US:CRL) Yahoo Finance·2026-02-18 17:33Core Insights - The company views New Approach Methodologies (NAMS) and AI as long-term enabling technologies rather than immediate disruptors to regulated safety assessment environments [1] - The acquisition of KF Cambodia is aimed at internalizing the NHP supply chain to secure future annual requirements and reduce volatile sourcing costs [2] Manufacturing Segment - Growth in the manufacturing segment was hindered by the loss of a major commercial cell therapy client, although Microbial Solutions maintained strong performance across all testing platforms [1] DSA Segment Performance - DSA segment demand showed non-linear recovery, with net book-to-bill improving to 1.12x in Q4, primarily driven by small and mid-sized biotech clients [2] - Revenue declines in Discovery Services were noted, while pricing and mix remained stable across the broader segment [1] Future Outlook - Performance stabilization in 2025 is expected as global biopharma clients resume pipeline urgency after 2024 spending pauses, alongside a late-year surge in biotech funding [2] - Guidance anticipates a return to organic revenue growth in the second half of 2026 for both the DSA segment and the consolidated company [2] Margin and Cost Management - Operating margin expansion is expected from the KF Cambodia acquisition, projected to contribute over 100 basis points to DSA margins for the full year, with improvements beginning in the second half [2] - The 2026 framework includes at least $100 million in incremental cost savings to offset annual cost inflation and protect margins during revenue recovery [2] RMS Revenue Projection - RMS revenue is projected to decline at a low-to-mid-single-digit rate due to the timing of NHP shipments and subdued CRADL occupancy from early-stage biotech [2] Capital Allocation Strategy - Capital allocation will focus on debt repayment and maintaining 'dry powder' for M&A opportunities in areas like bioanalysis and geographic expansion into China [2]